Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Propranolol in schizophrenia.

B B Sethi, S Dubé

    Progress in Neuro-Psychopharmacology & Biological Psychiatry
    |January 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    This study found d1-propranolol significantly reduced core schizophrenic symptoms within two weeks in 15 patients. Higher doses were well-tolerated, with only minor side effects observed.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Search for Charged Higgs Bosons Produced via Vector Boson Fusion and Decaying into a Pair of W and Z Bosons Using pp Collisions at sqrt[s]=13  TeV.

    Physical review letters·2017
    Same author

    Study of Jet Quenching with Z+jet Correlations in Pb-Pb and pp Collisions at sqrt[s]_{NN}=5.02  TeV.

    Physical review letters·2017
    Same author

    Search for Low Mass Vector Resonances Decaying to Quark-Antiquark Pairs in Proton-Proton Collisions at sqrt[s]=13  TeV.

    Physical review letters·2017
    Same author

    Searches for pair production of third-generation squarks in [Formula: see text][Formula: see text] pp collisions.

    The European physical journal. C, Particles and fields·2017
    Same author

    Measurement of the top quark mass using single top quark events in proton-proton collisions at [Formula: see text] TeV.

    The European physical journal. C, Particles and fields·2017
    Same author

    Measurement of double-differential cross sections for top quark pair production in pp collisions at [Formula: see text][Formula: see text] and impact on parton distribution functions.

    The European physical journal. C, Particles and fields·2017
    Same journal

    Mapping intrinsic neural timescale alterations in major depressive disorder.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    Same journal

    Probiotics in reducing negative symptoms of schizophrenia: A systematic review and meta-analysis.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    Same journal

    The IL10 rs1800872 polymorphism differentially modulates the relationship between plasma IL-10 levels and cognitive function in methamphetamine use disorder.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    Same journal

    Inflammatory differences and differential response to minocycline augmentation in young adult patients with first-episode drug-naïve melancholic and non-melancholic major depressive disorder.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    Same journal

    Beyond gray matter: unveiling the critical role of white matter in Alzheimer's disease.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    Same journal

    Chronic pain and stress: Transdiagnostic meta-analytic evidence of convergent network signature with PTSD.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    See all related articles

    Area of Science:

    • Psychiatry
    • Pharmacology

    Background:

    • Schizophrenia is a complex mental disorder with core symptoms impacting patients significantly.
    • Current treatments for schizophrenia have limitations and side effects.
    • Exploring novel therapeutic agents is crucial for improving patient outcomes.

    Purpose of the Study:

    • To evaluate the efficacy and tolerability of d1-propranolol in treating schizophrenic patients.
    • To assess the impact of d1-propranolol on core schizophrenic symptoms.

    Main Methods:

    • An open-label study involving 15 patients diagnosed with schizophrenia (ICD-9 criteria).
    • Patients received d1-propranolol with a fixed dose escalation up to 1920 mg/day by day 17.
    • Symptom severity was assessed using the CPRS and BPRS.

    Related Experiment Videos

    Main Results:

    • A statistically significant reduction in core schizophrenic symptoms, measured by CPRS and BPRS, was observed starting between weeks 1 and 2.
    • Higher doses of d1-propranolol were generally well-tolerated.
    • Serious bradycardia was an infrequent side effect, occurring in only 3 patients.

    Conclusions:

    • D1-propranolol demonstrates promising efficacy in rapidly reducing core symptoms of schizophrenia.
    • The drug appears to be well-tolerated at higher doses, suggesting a favorable safety profile.
    • Further research is warranted to explore the full therapeutic potential of d1-propranolol in schizophrenia management.